PHASEBIO PHARMACEUTICALS, INC.
11260 El Camino Real, Suite 100
San Diego, CA 92130
| January 6, 2020 | VIA EDGAR |
United States Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
Attn: Paul Fischer
| RE: | PhaseBio Pharmaceuticals, Inc. |
Registration Statement on FormS-3
File No. 333-235735
Acceleration Request
| Requested Date: | January 8, 2020 | |||||
| Requested Time: | 4:00 P.M. Eastern Time |
Ladies and Gentlemen:
In accordance with Rule 461 under the Securities Act of 1933, as amended, the undersigned registrant (the “Registrant”) hereby requests that the Securities and Exchange Commission take appropriate action to cause the above-referenced Registration Statement on FormS-3 (the “Registration Statement”) to become effective on January 8, 2020, at 4:00 p.m., Eastern Time, or as soon thereafter as is practicable.
Once the Registration Statement has been declared effective, please orally confirm that event with Madison Jones, counsel to the Registrant, at (202)728-7087.
Very truly yours,
PhaseBio Pharmaceuticals, Inc.
/s/ John Sharp |
| John Sharp |
| Chief Financial Officer |
cc: Jonathan P. Mow, Chief Executive Officer |
Kris Hanson, Vice President, Head of Legal |
Christian E. Plaza, Cooley LLP |
Darren K. DeStefano, Cooley LLP |
